Compiler backends are tasked with generating executable machine code for processors. With the proliferation of diverse processors, it is imperative for programmers to tailor specific compiler backends to accommodate each one.

Compiler backends are tasked with generating executable machine code for processors. With the proliferation of diverse processors, it is imperative for programmers to tailor specific compiler backends to accommodate each one.

Mark Zuckerberg is on a warpath to recruit top talent in the AI field for his newly formed Meta Superintelligence Labs. After trying to gut OpenAI (and successfully poaching several top researchers), he appears to have set his sights on his next target. More than a dozen people at Mira Murati's 50-person startup, Thinking Machines Lab, have been approached or received offers from the tech giant. One of those offers was more than 1 billion over a multi-year span, a source with knowledge of the negotiations tells WIRED. The rest were between 200 million and 500 million over a four-year span, multiple sources confirm.

Machine learning shows great potential in virtual screening for drug discovery. Current efforts on accelerating docking-based virtual screening do not consider using existing data of other previously developed targets. To make use of the knowledge of the other targets and take advantage of the existing data, in this work, we apply multi-task learning to the problem of docking-based virtual screening. With two large docking datasets, the results of extensive experiments show that multi-task learning can achieve better performances on docking score prediction. By learning knowledge across multiple targets, the model trained by multi-task learning shows a better ability to adapt to a new target. Additional empirical study shows that other problems in drug discovery, such as the experimental drug-target affinity prediction, may also benefit from multi-task learning. Our results demonstrate that multi-task learning is a promising machine learning approach for docking-based virtual screening and accelerating the process of drug discovery.

A number of projects are aimed at minimizing direct contact between health workers and patients. Temi had already identified a market for personal robotic assistants, costing about $2,000, that resemble an iPad on a parking-meter-high wheeled pedestal. Rafael and Elbit have now adapted them to operate in fleets, and to allow doctors to monitor patients or deliver them medicine without ever entering their rooms, said Yossi Wolf, who previously developed robots to help Israeli soldiers deal with Hamas tunnels or chemical weapons.

You've heard of chloroquine by now. Originally developed by German scientists in the 1930s, the anti-malaria drug is based on a natural compound present in the bark of certain South African trees. For nearly a century it's been saving lives globally, but remained under the radar of countries where malaria isn't a big problem. Thanks to Covid-19, chloroquine is back in the media spotlight as a potential treatment to reduce severe coronavirus symptoms. To be clear: we don't know if it works.

In health care, two exciting uses of artificial intelligence -- in the clinic for patient care and in the laboratory for drug discovery -- are remarkably different applications. That perhaps explains why, though it's still early days for both, they are developing at different rates. In the clinical setting, AI works with known parameters, typically running through a classification process based on experiences of what works and what doesn't for different types of patients. The potential of AI here is significant, and the early successes are truly exciting. The opportunity is equally compelling in drug discovery, particularly in areas of high unmet need such as rare and hard-to-treat cancers and neurodegenerative conditions.

First I will walk you through the app functionality and then will dive into implementation details. This app implements a business report execution time prediction use case (this time in JavaScript), which was explained in my previous post -- Report Time Execution Prediction with Keras and TensorFlow. For the model training, I'm using 50 epochs (data is processed in batches of 10) and the learning rate is set to 0.001. Neural Network is based on two processing layers and one output layer. Model is trained to forecast the expected wait time for business report execution.

Curiosity as a means to explore during reinforcement learning problems has recently become very popular. However, very little progress has been made in utilizing curiosity for learning control. In this work, we propose a model-based reinforcement learning (MBRL) framework that combines Bayesian modeling of the system dynamics with curious iLQR, a risk-seeking iterative LQR approach. During trajectory optimization the curious iLQR attempts to minimize both the task-dependent cost and the uncertainty in the dynamics model. We scale this approach to perform reaching tasks on 7-DoF manipulators, to perform both simulation and real robot reaching experiments. Our experiments consistently show that MBRL with curious iLQR more easily overcomes bad initial dynamics models and reaches desired joint configurations more reliably and with less system rollouts.

China, in a bid to be the biggest big brother of them all, has expanded its already massive facial recognition AI system. What a great idea: Students at the Hangzhou No. 11 middle school are being monitored by a set of three AI-powered cameras that provide real-time emotional recognition and analysis. According to a report from Hangzhou.com, the system is quite robust: How much time do you have in one day? What are you doing when you are not focused? Which teachers' classes do students like most?